Epigenomics appoints new US head
This article was originally published in Clinica
Executive Summary
German cancer diagnostics specialist Epigenomics has appointed Noel Doheny as CEO of its US subsidiary. Mr Doheny has over 30 years' experience in diagnostics. He was most recently CEO of molecular diagnostics company OpGen and has held other senior management positions at Affymetrix and Qiagen. Mr Doheny will start his new role at Seattle, Washington-based Epigenomics Inc next month and help to build its US sales force as the company prepares to submit its premarket approval application to the FDA for its Epi proColon 2.0 coloeretal cancer test.